Who is sponsoring OASES?

OASES is sponsored by Gongwin Biopharm Co., Ltd..

What condition does OASES study?

OASES studies Hepatocellular Carcinoma.

What drugs are being tested in OASES?

Interventions: Para-Toluenesulfonamide.

Last reviewed 2023-09-11 · How we verify

A Phase II Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy (OASES)

NCT03447951 Phase 2 UNKNOWN

This study is being performed to evaluate the efficacy and safety of 30% PTS100 of total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma patients who are ineligible for operation or local regional therapy.

Details

Lead sponsor	Gongwin Biopharm Co., Ltd.
Phase	Phase 2
Status	UNKNOWN
Enrolment	33
Start date	2018-06-19
Completion	2025-12

Conditions

Hepatocellular Carcinoma

Interventions

Para-Toluenesulfonamide

Primary outcomes

Objective Response Rate (ORR) — 4-week post treatment
To evaluate the efficacy, measured by objective response rate (ORR) of pooled treatment groups based on the modified RECIST (mRECIST) criteria at concluding visit.

Countries

Taiwan